Insmed Incorporated
INSM
$70.20
-$0.87-1.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 24.79% | 18.15% | 16.98% | 15.77% | 41.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.79% | 18.15% | 16.98% | 15.77% | 41.13% |
| Cost of Revenue | 41.79% | 26.72% | 26.33% | 26.23% | 41.12% |
| Gross Profit | 19.99% | 15.86% | 14.42% | 12.96% | 41.14% |
| SG&A Expenses | 59.18% | 31.23% | 26.22% | 16.50% | 21.84% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -0.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.98% | 34.18% | -7.92% | 4.50% | 15.85% |
| Operating Income | -50.83% | -43.32% | 16.59% | 0.16% | -6.07% |
| Income Before Tax | -26.60% | -38.59% | -22.72% | 1.74% | -15.67% |
| Income Tax Expenses | 26.85% | 86.40% | 58.11% | 21.95% | 698.40% |
| Earnings from Continuing Operations | -26.60% | -38.75% | -22.79% | 1.67% | -16.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.60% | -38.75% | -22.79% | 1.67% | -16.20% |
| EBIT | -50.83% | -43.32% | 16.59% | 0.16% | -6.07% |
| EBITDA | -51.53% | -44.05% | 16.80% | 0.38% | -6.26% |
| EPS Basic | -2.40% | -14.13% | -9.18% | 9.69% | -6.48% |
| Normalized Basic EPS | -18.96% | -12.78% | 24.46% | 8.35% | 4.08% |
| EPS Diluted | -2.40% | -14.19% | -9.16% | 9.53% | -6.48% |
| Normalized Diluted EPS | -18.96% | -12.78% | 24.46% | 8.35% | 4.08% |
| Average Basic Shares Outstanding | 23.63% | 21.57% | 12.47% | 8.87% | 9.13% |
| Average Diluted Shares Outstanding | 23.63% | 21.57% | 12.47% | 8.87% | 9.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |